Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Novartis Focalin Price Similar To Ritalin; ADHD Drug Clears FDA Nov. 13

  • News

Executive Summary

Novartis' Focalin will be priced similarly to its parent compound Ritalin, the company said following the Nov. 13 approval of the attention deficit hyperactivity disorder drug

You may also be interested in...



Ritalin LA Will Be Novartis’ Second Marketed Once-Daily Methylphenidate

Novartis' Ritalin LA will be the company's second once-daily methylphenidate formulation on the market

Ritalin LA Will Be Novartis’ Second Marketed Once-Daily Methylphenidate

Novartis' Ritalin LA will be the company's second once-daily methylphenidate formulation on the market

Ritalin LA "approvable" letter

Novartis and Celgene expect to launch once-daily formulation of methylphenidate (Ritalin LA) during the fourth quarter after responding to Oct. 2 "approvable" letter from FDA

Table

View full table

Related Content

Pink Sheet
Tags:
Latest Headlines

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

See All
UsernamePublicRestriction

Register

PS038870

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By